U.S. Department of Health & Human Services Divider Arrow National Institutes of Health Divider Arrow NCATS

Details

Stereochemistry ACHIRAL
Molecular Formula C8H10N6
Molecular Weight 190.2052
Optical Activity NONE
Defined Stereocenters 0 / 0
E/Z Centers 0
Charge 0

SHOW SMILES / InChI
Structure of DIHYDRALAZINE

SMILES

NNC1=C2C=CC=CC2=C(NN)N=N1

InChI

InChIKey=VQKLRVZQQYVIJW-UHFFFAOYSA-N
InChI=1S/C8H10N6/c9-11-7-5-3-1-2-4-6(5)8(12-10)14-13-7/h1-4H,9-10H2,(H,11,13)(H,12,14)

HIDE SMILES / InChI

Description

Dihydralazine is a compound with antihypertensive properties and is in clinical trials, where is studied its effect on kidney function and hormones in healthy individuals.

Approval Year

Unknown
139594
Conditions

Conditions

ConditionModalityTargetsHighest PhaseProduct
Primary
Not Provided
504
Unknown

Approved Use

Unknown
PubMed

PubMed

TitleDatePubMed
Ketanserin for the treatment of preeclampsia.
2001
[Reversible loss of vision in severe preeclampsia: case report and review of the literature].
2003 Nov-Dec
3,6-Bis(2-pyridyl)di-1,2,4-triazolo[3,4-a:4',3'-c]phthalazine.
2004 Sep
Morbidity and development in childhood of infants born after temporising treatment of early onset pre-eclampsia.
2005 Jul
Evaluation of a strict protocol approach in managing women with severe disease due to hypertension in pregnancy: a before and after study.
2005 Sep 30
Changes in metabolism and blood flow following catecholamine stimulation in the synovial membrane measured with microdialysis.
2006 Feb
Nitric oxide-deficiency regulates hepatic heme oxygenase-1.
2008 Feb
Regression of glomerulosclerosis in subtotally nephrectomized rats: effects of monotherapy with losartan, spironolactone, and their combination.
2008 Jul
Effects of dihydralazine on renal water and aquaporin-2 excretion in humans.
2009
[Drugs during preeclampsia. Fetal risks and pharmacology].
2010 Apr
Autoimmune hepatitis triggered by nitrofurantoin: a case series.
2010 Sep 23
Patents

Patents

04152435
9

Sample Use Guides

In Vivo Use Guide
The influence of a pure afterload reduction on systolic time intervals and various echocardiographic indices was assessed in six healthy volunteers, who underwent a single blind placebo controlled trial of three regimens of intravenous dihydralazine (6.25, 12.5, and 25.0 mg).
Route of Administration: Intravenous
In Vitro Use Guide
Curator's Comment: In mice bone marrow cells, dihydralazine induced a modest but statistically significant increase over controls in the frequency of sister chromatid exchanges, the rank of potencies being in this case dihydralazine greater than endralazine greater than hydralazine. In the Ames reversion test all three drugs behaved as direct-acting mutagens of low potency, whose activity was not influenced by rat liver nor by mouse liver or lung S-9 fractions. Hydralazine and dihydralazine elicited mixed genetic mechanisms of mutations, while endralazine exclusively induced frameshift errors in Salmonella DNA.
Unknown
Name Type Language
DIHYDRALAZINE
INN   MI   WHO-DD  
INN  
Official Name English
Dihydralazine [WHO-DD]
Common Name English
dihydralazine [INN]
Common Name English
2,3-DIHYDRO-1,4-PHTHALAZINEDIONE DIHYDRAZONE
Systematic Name English
NSC-526654
Code English
DIHYDRALAZINE [MI]
Common Name English
1,4-DIHYDRAZINOPHTHALAZINE
Systematic Name English
Classification Tree Code System Code
WHO-VATC QC02DB01
Created by admin on Fri Dec 15 17:03:03 GMT 2023 , Edited by admin on Fri Dec 15 17:03:03 GMT 2023
WHO-ATC C02DB01
Created by admin on Fri Dec 15 17:03:03 GMT 2023 , Edited by admin on Fri Dec 15 17:03:03 GMT 2023
WHO-ATC C02LG01
Created by admin on Fri Dec 15 17:03:03 GMT 2023 , Edited by admin on Fri Dec 15 17:03:03 GMT 2023
WHO-ATC C02LG51
Created by admin on Fri Dec 15 17:03:03 GMT 2023 , Edited by admin on Fri Dec 15 17:03:03 GMT 2023
WHO-VATC QC02LG01
Created by admin on Fri Dec 15 17:03:03 GMT 2023 , Edited by admin on Fri Dec 15 17:03:03 GMT 2023
WHO-VATC QC02LG51
Created by admin on Fri Dec 15 17:03:03 GMT 2023 , Edited by admin on Fri Dec 15 17:03:03 GMT 2023
NCI_THESAURUS C270
Created by admin on Fri Dec 15 17:03:03 GMT 2023 , Edited by admin on Fri Dec 15 17:03:03 GMT 2023
Code System Code Type Description
SMS_ID
100000082625
Created by admin on Fri Dec 15 17:03:03 GMT 2023 , Edited by admin on Fri Dec 15 17:03:03 GMT 2023
PRIMARY
ChEMBL
CHEMBL35505
Created by admin on Fri Dec 15 17:03:03 GMT 2023 , Edited by admin on Fri Dec 15 17:03:03 GMT 2023
PRIMARY
RXCUI
3409
Created by admin on Fri Dec 15 17:03:03 GMT 2023 , Edited by admin on Fri Dec 15 17:03:03 GMT 2023
PRIMARY RxNorm
NSC
526654
Created by admin on Fri Dec 15 17:03:03 GMT 2023 , Edited by admin on Fri Dec 15 17:03:03 GMT 2023
PRIMARY
EPA CompTox
DTXSID0022935
Created by admin on Fri Dec 15 17:03:03 GMT 2023 , Edited by admin on Fri Dec 15 17:03:03 GMT 2023
PRIMARY
MESH
D004078
Created by admin on Fri Dec 15 17:03:03 GMT 2023 , Edited by admin on Fri Dec 15 17:03:03 GMT 2023
PRIMARY
MERCK INDEX
m4457
Created by admin on Fri Dec 15 17:03:03 GMT 2023 , Edited by admin on Fri Dec 15 17:03:03 GMT 2023
PRIMARY Merck Index
CAS
484-23-1
Created by admin on Fri Dec 15 17:03:03 GMT 2023 , Edited by admin on Fri Dec 15 17:03:03 GMT 2023
PRIMARY
FDA UNII
PCU411F5L6
Created by admin on Fri Dec 15 17:03:03 GMT 2023 , Edited by admin on Fri Dec 15 17:03:03 GMT 2023
PRIMARY
ECHA (EC/EINECS)
207-605-0
Created by admin on Fri Dec 15 17:03:03 GMT 2023 , Edited by admin on Fri Dec 15 17:03:03 GMT 2023
PRIMARY
WIKIPEDIA
Dihydralazine
Created by admin on Fri Dec 15 17:03:03 GMT 2023 , Edited by admin on Fri Dec 15 17:03:03 GMT 2023
PRIMARY
NCI_THESAURUS
C97307
Created by admin on Fri Dec 15 17:03:03 GMT 2023 , Edited by admin on Fri Dec 15 17:03:03 GMT 2023
PRIMARY
PUBCHEM
10230
Created by admin on Fri Dec 15 17:03:03 GMT 2023 , Edited by admin on Fri Dec 15 17:03:03 GMT 2023
PRIMARY
DRUG BANK
DB12945
Created by admin on Fri Dec 15 17:03:03 GMT 2023 , Edited by admin on Fri Dec 15 17:03:03 GMT 2023
PRIMARY
EVMPD
SUB07137MIG
Created by admin on Fri Dec 15 17:03:03 GMT 2023 , Edited by admin on Fri Dec 15 17:03:03 GMT 2023
PRIMARY
INN
245
Created by admin on Fri Dec 15 17:03:03 GMT 2023 , Edited by admin on Fri Dec 15 17:03:03 GMT 2023
PRIMARY
DRUG CENTRAL
884
Created by admin on Fri Dec 15 17:03:03 GMT 2023 , Edited by admin on Fri Dec 15 17:03:03 GMT 2023
PRIMARY
ACTIVE MOIETY
Structure of DIHYDRALAZINE
SALT/SOLVATE (PARENT)
Structure of DIHYDRALAZINE SULFATE
SALT/SOLVATE (PARENT)
Structure of DIHYDRALAZINE MESYLATE
SALT/SOLVATE (PARENT)
Structure of DIHYDRALAZINE HYDROCHLORIDE
NIH
NCATS
PRIVACY ACT
ACCESSIBILITY
DISCLAIMER
HHS VULNERABILITY DISCLOSURE
For language access assistance, contact the NCATS Public Information Officer
National Center for Advancing Translational Sciences (NCATS),
6701 Democracy Boulevard, Bethesda MD 20892-4874 • 301-594-8966